Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SREBP1C_FN_CTL

Financiado

Cerrado

Characterising the role of mammalian Target Of Rapamcyin Complex 1 mTORC1 Sreb...

Characterising the role of mammalian Target Of Rapamcyin Complex 1 mTORC1 Srebp1c signaling in directing the differentiation and function of T lymphocytes Modulating immune responses by shifting the balance of effector versus regulatory/memory T cells has significant potential as therapy for various autoimmune diseases and preventing organ transplant rejection. The mammalian Target... ver más

31/07/2016

TRINITY COLLEGE DU...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TRINITY COLLEGE DUBLIN

0.00€ | Lider

Proyectos interesantes

menTORingTregs

Medical Technol...

Data Science

2M€ Cerrado

Th17 tissue metab

Medical Technol...

Data Science

266K€ Cerrado

SAF2013-42772-R

Medical Technol...

Data Science

121K€ Cerrado

SAF2011-23317

Medical Technol...

Immunology

169K€ Cerrado

Allo-THYTECH

Medical Technol...

Data Science

173K€ Cerrado

RTI2018-097414-B-I00

Medical Technol...

Immunology

182K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Modulating immune responses by shifting the balance of effector versus regulatory/memory T cells has significant potential as therapy for various autoimmune diseases and preventing organ transplant rejection. The mammalian Target Of Rapamycin Complex 1 (mTORC1) has diverse effects in T cells and can function to direct T cell fate. Direct mTORC1 inhibition provides potent immunosuppression but is associated with significant toxicity. Dissecting the mechanisms that account for the multiple mTORC1 effects on T cell differentiation is required to develop targeted therapies that provide desirable immunomodulatory effects without the toxicity associated with rapamycin treatment. The function of activated T cells is closely linked to their elevated metabolic state. Thus, inhibition of T cell metabolism via disruption of glucose metabolism or amino acid availability can alter T cell function. mTORC1 activity is acutely sensitive to the metabolic cues and has established roles in regulating cellular metabolism in other systems, through the control of Hypoxia Inducible Factor 1α (HIF1α) and Sterol Response Element Binding Protein 1c (Srebp1c) transcriptional activity. Based on the hypothesis that mTORC1 integrates the control of T cell metabolism and differentiation via common pathways, our data reveals a dual role for mTORC1/HIF1α in controlling glucose metabolism and CD8 T cell function. Lipid metabolism, controlled by mTORC1/Srebp1c in other cellular systems, has also been linked to T cell differentiation. Preliminary results demonstrate that activated T cells contain active mTORC1/Srebp1c signaling and suggest mTORC1 activity controls Srebp1c target genes, supporting a potential role for mTORC1/Srebp1c in the control of T cell function. This project aims to characterize the role for mTORC1/Srebp1c in the activation, differentiation and function of T lymphocytes using complementary pharmacological and genetic approaches and using state of the art in vivo technologies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores